Tania Dempsey, MD, discusses mast cell activation syndrome., which may be a consideration if a patient has not responded to anything else. Simple methods for treating and assessing patients are discussed.
In an interview conducted at the 2024 Congress of the European Hematology Association in Madrid, Spain, Lindsay Rein, MD, Duke University Medical Center, Durham, North Carolina, provided insights…
In an expert roundtable discussion, Matthew P. Giannetti, MD, Harvard Medical School, Brigham and Women’s Hospital Mastocytosis Center, Boston, Massachusetts; Lauren M. Madigan, MD, University of Utah, University…
Systemic mastocytosis, a rare blood disorder, affects the entire body. There are many challenges associated with living with this systemic mastocytosis that are centered around reducing the frequency…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
